Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zomiradomide · KT-413

Small molecule (Molecular glue degrader) · Degrader of IRAK4, Ikaros (IKZF1) and Aiolos (IKZF3) · developed by Kymera Therapeutics

Phase 1 Most advanced trial (none active)
KYMR Developer
1 Registered trials

What is Zomiradomide?

Zomiradomide (KT-413) is a small molecule protein degrader that recruits the E3 ubiquitin ligase to tag IRAK4, Ikaros (IKZF1) and Aiolos (IKZF3) for proteasomal degradation. It is being studied in non-Hodgkin lymphoma, including diffuse large B-cell lymphoma with MYD88 mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KT-413
Drug type
Small molecule (Molecular glue degrader)
Targets
IRAK4, Ikaros (IKZF1), Aiolos (IKZF3), MYD88 (biomarker)
Mechanism
Degrader of IRAK4, Ikaros (IKZF1) and Aiolos (IKZF3)
Pathways
NF-kB signaling, TLR signaling, IL-1R signaling, IRF4 downregulation and type I interferon signaling, apoptosis
Therapy area
Oncology
Developer
Kymera Therapeutics, Inc. (KYMR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05233033 Phase 1 Non Hodgkin Lymphoma Completed KYMR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B Cell LymphomaDLBCLMYD88 Gene MutationNon Hodgkin Lymphoma

Other drugs acting on IRAK4 / IKZF1 / IKZF3

More from Kymera Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.

Follow KYMR, the company behind Zomiradomide

See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYMR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.